• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌的创新与挑战:第二届剑桥会议总结声明

Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.

作者信息

Atkins Michael B, Ernstoff Marc S, Figlin Robert A, Flaherty Keith T, George Daniel J, Kaelin William G, Kwon Eugene D, Libermann Towia A, Linehan W Marston, McDermott David F, Ochoa Augusto C, Pantuck Allan J, Rini Brian I, Rosen Mark A, Sosman Jeffrey A, Sukhatme Vikas P, Vieweg Johannes W, Wood Christopher G, King Laura

机构信息

Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

出版信息

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s. doi: 10.1158/1078-0432.CCR-06-2231.

DOI:10.1158/1078-0432.CCR-06-2231
PMID:17255291
Abstract

Innovations and Challenges in Renal Cancer, chaired by Michael B. Atkins, was held April 28 to 29, 2006 in Cambridge, Massachusetts. The conference brought together leading experts in the fields of cancer research, medical oncology, urology, immunology, radiology, and immunotherapy, with the goal of advancing the field of renal cancer treatment by critiquing new data from ongoing clinical trials and stimulating communication among those involved in basic and clinical research. The conference proceedings published in this educational supplement to Clinical Cancer Research are intended to provide timely information and recommendations on important aspects of renal cancer genetics and biology and advances in prognostic classification and treatment.

摘要

由迈克尔·B·阿特金斯主持的“肾癌的创新与挑战”会议于2006年4月28日至29日在马萨诸塞州剑桥市举行。该会议汇聚了癌症研究、医学肿瘤学、泌尿学、免疫学、放射学和免疫疗法领域的顶尖专家,目的是通过评估正在进行的临床试验的新数据以及促进基础研究和临床研究人员之间的交流,推动肾癌治疗领域的发展。发表在《临床癌症研究》这本教育增刊上的会议论文集旨在提供有关肾癌遗传学和生物学重要方面以及预后分类和治疗进展的及时信息和建议。

相似文献

1
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.肾细胞癌的创新与挑战:第二届剑桥会议总结声明
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s. doi: 10.1158/1078-0432.CCR-06-2231.
2
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.黑色素瘤的创新与挑战:首届剑桥会议总结声明
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s. doi: 10.1158/1078-0432.CCR-05-2560.
3
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.肾癌的创新与挑战:第三届剑桥会议总结声明
Cancer. 2009 May 15;115(10 Suppl):2247-51. doi: 10.1002/cncr.24229.
4
[Prognostic factors in kidney cancer].
Prog Urol. 2007 Feb;17(1 Suppl 1):139-43.
5
Renal cell carcinoma.肾细胞癌
World J Urol. 2008 Apr;26(2):113. doi: 10.1007/s00345-008-0248-1. Epub 2008 Apr 4.
6
Novel therapeutics for metastatic renal cell carcinoma.转移性肾细胞癌的新型疗法
Cancer. 2009 May 15;115(10 Suppl):2361-7. doi: 10.1002/cncr.24235.
7
Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.肾细胞癌的多模态治疗模式:手术与靶向药物对比
Expert Rev Anticancer Ther. 2009 Jun;9(6):763-71. doi: 10.1586/era.09.37.
8
New therapeutic developments in renal cell cancer.肾细胞癌的新治疗进展。
Crit Rev Oncol Hematol. 2009 Jan;69(1):56-63. doi: 10.1016/j.critrevonc.2008.07.007. Epub 2008 Aug 26.
9
Renal cell carcinoma: current status and emerging therapies.肾细胞癌:现状与新兴疗法
Cancer Treat Rev. 2007 May;33(3):299-313. doi: 10.1016/j.ctrv.2006.12.005. Epub 2007 Feb 27.
10
Prognostic markers in renal cell carcinoma.肾细胞癌的预后标志物
Curr Opin Urol. 2007 Sep;17(5):303-8. doi: 10.1097/MOU.0b013e328277f180.

引用本文的文献

1
The Underestimated Role of the p53 Pathway in Renal Cancer.p53通路在肾癌中被低估的作用
Cancers (Basel). 2022 Nov 22;14(23):5733. doi: 10.3390/cancers14235733.
2
G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas.G3BP1 通过 IL-6/G3BP1/STAT3 信号轴促进肾细胞癌的肿瘤进展和转移。
Cell Death Dis. 2018 May 1;9(5):501. doi: 10.1038/s41419-018-0504-2.
3
Long Noncoding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Renal Cell Carcinoma Progression via Sponging miRNA-429.
长链非编码 RNA 转移相关肺腺癌转录本 1(MALAT1)通过海绵吸附 miRNA-429 促进肾细胞癌进展。
Med Sci Monit. 2018 Mar 28;24:1794-1801. doi: 10.12659/MSM.909450.
4
Establishment of a bioluminescent Renca cell line for renal carcinoma research.建立用于肾癌研究的生物发光 Renca 细胞系。
Int Urol Nephrol. 2018 Jan;50(1):55-61. doi: 10.1007/s11255-017-1707-7. Epub 2017 Oct 3.
5
C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.C1QBP通过调控YBX1抑制雄激素受体(AR)增强的肾癌细胞侵袭。
Neoplasia. 2017 Feb;19(2):135-144. doi: 10.1016/j.neo.2016.12.003. Epub 2017 Jan 17.
6
Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.雄激素受体(AR)抑制miRNA-145以促进肾细胞癌(RCC)进展,且与VHL状态无关。
Oncotarget. 2015 Oct 13;6(31):31203-15. doi: 10.18632/oncotarget.4522.
7
RLIP76 Targeted Therapy for Kidney Cancer.肾癌的RLIP76靶向治疗。
Pharm Res. 2015 Oct;32(10):3123-36. doi: 10.1007/s11095-015-1723-1. Epub 2015 May 29.
8
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis.G 蛋白偶联受体 CLR 在透明细胞肾细胞癌中与肾上腺髓质素形成自分泌环路而上调,并与不良预后相关。
Clin Cancer Res. 2013 Oct 15;19(20):5740-8. doi: 10.1158/1078-0432.CCR-13-1712. Epub 2013 Aug 22.
9
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine.肾细胞癌患者接受白细胞介素-2、干扰素-α和树突状细胞疫苗治疗后外周血淋巴细胞的基因表达谱。
PLoS One. 2012;7(12):e50221. doi: 10.1371/journal.pone.0050221. Epub 2012 Dec 3.
10
Automated noninvasive classification of renal cancer on multiphase CT.多期 CT 自动无创肾癌分类。
Med Phys. 2011 Oct;38(10):5738-46. doi: 10.1118/1.3633898.